Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sutro Biopharma, Inc. (STRO)
Price$20.07Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M | $42.7M | $42.7M | $38.4M | $51.7M | $59.7M |
| Research & development | $166.4M | $252.0M | $180.4M | $137.2M | $104.4M | $77.0M | $65.6M | $54.3M | $54.6M | $43.5M |
| Operating expenses | $260.9M | $300.5M | $243.0M | $196.7M | $160.4M | $113.8M | $98.2M | $75.6M | $71.0M | $58.4M |
| Operating income | −$158.4M | −$238.5M | −$89.3M | −$128.9M | −$98.5M | −$71.1M | −$55.5M | −$37.2M | −$19.3M | $1.4M |
| Operating margin | −154.53% | −384.34% | −58.07% | −190.26% | −159.22% | −166.32% | −129.79% | −96.89% | −37.25% | 2.28% |
| EBITDA | −$151.0M | −$231.2M | −$82.5M | −$123.3M | −$93.7M | −$66.8M | −$50.7M | −$32.7M | −$14.3M | $7.0M |
| EBITDA margin | −147.38% | −372.70% | −53.64% | −181.86% | −151.39% | −156.27% | −118.61% | −85.07% | −27.60% | 11.76% |
| Net income | −$191.1M | −$227.5M | −$106.8M | −$119.2M | −$105.5M | −$32.1M | −$119.2M | −$35.3M | −$19.7M | $1.7M |
| Net profit margin | −186.45% | −366.62% | −69.47% | −175.89% | −170.55% | −75.20% | −278.93% | −91.93% | −38.05% | 2.85% |
| Basic EPSper basic share | -$22.49 | -$29.40 | -$17.80 | -$23.50 | -$22.90 | -$9.90 | -$24.30 | -$61.30 | -$439.50 | $0.00 |
| Diluted EPSper diluted share | -$22.49 | -$29.40 | -$17.80 | -$23.50 | -$22.90 | -$9.90 | -$24.30 | -$61.30 | -$439.50 | $0.00 |
Owners
Reported shareholders
7.87%of listed shares
PERCEPTIVE ADVISORS LLC1.3M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
PERCEPTIVE ADVISORS LLC | 7.87%1.3M shares |
BVF INC/IL | 7.55%1.25M shares |
Affinity Asset Advisors, LLC | 7.07%1.17M shares |
BlackRock, Inc. | 6.77%1.12M shares |
SAMSARA BIOCAPITAL, LLC | 6.41%1.06M shares |
Kynam Capital Management, LP | 5.26%872.56K shares |
ORBIMED ADVISORS LLC | 4.49%743.94K shares |
Balyasny Asset Management L.P. | 4.29%711.16K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.19%694.22K shares |
EVENTIDE ASSET MANAGEMENT, LLC | 3.53%585.26K shares |
Velan Capital Investment Management LP | 3.09%512.16K shares |
Woodline Partners LP | 2.76%458.03K shares |
NEWELL WILLIAM J | ≈2.47%409.06K shares |
ADAR1 Capital Management, LLC | 2.44%404.01K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.35%389.69K shares |
ACADIAN ASSET MANAGEMENT LLC | 2.26%373.84K shares |
MILLENNIUM MANAGEMENT LLC | 2.21%365.97K shares |
STATE STREET CORP | 1.85%305.98K shares |
Merck & Co., Inc. | 1.64%272.35K shares |
ACUTA CAPITAL PARTNERS, LLC | 1.63%270.25K shares |
Percentages use 16.58M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 15, 2025Form 4 | Pauling DavidChief Admin. Ofcr. & GC | BuyCommon Stock | 12.5K | $0.80 | $10.0K | 71.7K |
| Oct 15, 2025Form 4 | Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER | BuyCommon Stock | 17.0K | $0.80 | $13.6K | 71.8K |
| Oct 15, 2025Form 4 | Chung JaneChief Executive Officer | BuyCommon Stock | 12.5K | $0.80 | $10.0K | 122.8K |
| Oct 15, 2025Form 4 | Chow Gregory K.CFO | BuyCommon Stock | 19.8K | $0.81 | $16.0K | 19.8K |
| Oct 15, 2025Form 4 | MATSUI CONNIEDirector | BuyCommon Stock | 50.0K | $0.80 | $40.0K | 50.0K |